Top Ten Tips Palliative Care Clinicians Should Know About Acute Myeloid Leukemia.

Autor: Patel RV; Division of Hematology and Oncology, The University of Alabama at Birmingham, Birmingham, Alabama, USA., Ali F; Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, USA., Chiad Z; Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, USA., Chojecki AL; Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, USA., Webb JA; Section of Palliative Care, Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon, USA., Rosa WE; Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, New York, USA., LeBlanc TW; Duke Cancer Institute, Duke University, Durham, North Carolina, USA.

Publikováno v: Journal of palliative medicine [J Palliat Med] 2024 Jun; Vol. 27 (6), pp. 794-801. Date of Electronic Publication: 2023 Dec 08.

Outcomes and hospitalization patterns of patients with acute myelogenous leukemia treated with frontline CPX-351 or HMA/venetoclax.

Autor: Chojecki AL; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA. Electronic address: Aleksander.Chojecki@atriumhealth.org., Arnall J; Atrium Health Specialty Pharmacy Service, Atrium Health, Charlotte, NC, USA., Boselli D; Department of Cancer Biostatistics, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA., Patel R; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA., Chiad Z; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA., DiSogra KY; Atrium Health Specialty Pharmacy Service, Atrium Health, Charlotte, NC, USA., Karabinos A; Atrium Health Specialty Pharmacy Service, Atrium Health, Charlotte, NC, USA., Chen T; Department of Cancer Biostatistics, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA., Cruz A; Department of Cancer Biostatistics, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA., Verbyla A; Department of Cancer Biostatistics, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA., Ai J; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA., Knight TG; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA., Ragon BK; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA., Shah NA; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA., Sanikommu SR; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA., Symanowski J; Department of Cancer Biostatistics, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA., Avalos BR; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA., Copelan EA; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA., Grunwald MR; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA.

Publikováno v: Leukemia research [Leuk Res] 2022 Aug; Vol. 119, pp. 106904. Date of Electronic Publication: 2022 Jun 21.